Nyxoah

NYXH · NASDAQ · Healthcare / Medical Devices

0.8995USD+0.00 (+0.48%)

Price History

Full chart

Market Stats

Previous Close0.8952

Open0.898

Day Range0.8754 – 0.90

52-Week Range1.26 – 6.87

Volume123.13K

Market Cap147.67M

P/E (TTM)0.00

Forward P/E0.00

EPS-2.49

Dividend Yield0.00%

Beta0.96

50-Day Avg1.52

200-Day Avg2.97

About

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Company Details

SectorHealthcare
IndustryMedical Devices
CEOMr. Robert Taub MBA
Employees153
HeadquartersRue Edouard Belin 12, Mont-Saint-Guibert, Belgium, 1435, USA
Websitehttps://www.nyxoah.com

Leadership

Mr. Robert Taub MBACo-Founder & Chairman · b. 1947
Mr. Bruno OnkelinxChief Technical Officer · b. 1972
Mr. John LandryChief Financial Officer · b. 1973
Mr. Jeyakumar SubbaroyanChief Science Officer
Ms. An MoonenGeneral Counsel
Ms. Geeta KavetiChief Compliance Officer
Mr. Loic MoreauPresident of International · b. 1980
Dr. Maurits S. BoonChief Medical Officer
Mr. Scott HolstineChief Commercial Officer · b. 1971
Ms. Ashlea MittelstaedtChief Strategy Officer

Financials

Income Statement

Currency: EUR	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	69.00K	852.00K	3.08M	4.35M	4.52M	10.02M
Growth (%)	-	-	-	-	+1134.78%	+261.97%	+40.99%	+3.98%	+121.63%
Cost of Revenue	89.25K	95.08K	486.04K	30.00K	303.00K	1.15M	1.66M	1.55M	3.69M
Gross Profit	-89.25K	-95.08K	-486.04K	39.00K	549.00K	1.93M	2.69M	2.97M	6.33M
Gross Margin	-	-	-	56.52%	64.44%	62.71%	61.91%	65.67%	63.13%
Operating Expense	10.05M	8.35M	8.03M	11.26M	26.79M	34.43M	47.79M	61.78M	89.27M
Operating Income	-10.14M	-8.45M	-8.52M	-11.22M	-26.24M	-32.50M	-45.10M	-58.81M	-82.94M
Operating Margin	-	-	-	-16266.67%	-3080.05%	-1053.79%	-1037.30%	-1300.80%	-827.76%
EBITDA	-8.65M	-8.49M	-8.22M	-10.60M	-22.59M	-27.89M	-42.08M	-53.77M	-82.90M
EBITDA Margin	-	-	-	-15368.12%	-2651.53%	-904.25%	-967.80%	-1189.23%	-827.36%
Net Income	-10.37M	-9.08M	-8.45M	-12.24M	-27.62M	-31.23M	-43.21M	-59.24M	-90.08M
Net Income Margin	-	-	-	-17746.38%	-3241.67%	-1012.48%	-993.84%	-1310.24%	-899.05%
R&D	1.53M	1.37M	1.64M	2.91M	5.95M	15.86M	27.66M	34.33M	42.82M
R&D as % of Total Revenue	-	-	-	4217.39%	698.59%	514.30%	636.06%	759.23%	427.39%
Interest Expense	37.00K	29.00K	701.56K	198.00K	386.00K	237.00K	1.21M	1.90M	1.69M
Interest Expense % of Total Revenue	-	-	-	286.96%	45.31%	7.68%	27.76%	42.09%	16.88%

Balance Sheet

Currency: EUR	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	11.14M	17.98M	17.06M	139.58M	170.83M	146.07M	124.16M	158.41M	118.43M
Total Liabilities	6.62M	7.53M	14.41M	20.67M	22.21M	25.75M	26.14M	45.15M	69.34M
Total Equity	4.53M	10.45M	2.65M	118.92M	148.62M	120.32M	98.02M	113.25M	49.11M
Cash	10.11M	16.80M	6.57M	112.93M	135.51M	17.89M	21.61M	34.19M	29.99M
Total Debt	5.26M	5.82M	9.65M	14.12M	11.68M	11.88M	12.70M	22.65M	42.06M
Net Debt	-4.84M	-10.99M	3.08M	-98.81M	-123.83M	-6.01M	-8.91M	-11.53M	12.07M

Cash Flow

Currency: EUR	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-8.29M	-8.14M	-5.93M	-6.86M	-25.34M	-28.76M	-44.78M	-49.23M	-67.50M
Investing Cash Flow	-91.00K	-75.00K	-5.79M	-10.69M	-11.82M	-89.95M	32.01M	-16.32M	26.17M
Financing Cash Flow	1.11M	15.00M	700.00K	104.03M	76.47M	-983.00K	16.86M	77.44M	38.79M
Capital Expenditure	91.00K	77.00K	5.79M	10.68M	11.82M	16.35M	10.96M	6.07M	804.70K
Free Cash Flow	-8.38M	-8.22M	-11.72M	-17.54M	-37.15M	-45.10M	-55.74M	-55.30M	-68.30M
Dividends Paid	-	-	-	0	0	0	0	0	0
FCF to OCF	101.10%	100.95%	197.52%	255.59%	146.64%	156.85%	124.48%	112.33%	101.19%
Dividend Paid to FCF	-	-	-	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Earnings

Report Date	Mar 31, 2019	Jun 30, 2019	Sep 30, 2019	Dec 31, 2019	Mar 31, 2020	Aug 10, 2020	Dec 31, 2020	Mar 31, 2021	Jun 10, 2021	Aug 31, 2021	Nov 24, 2021	Mar 24, 2022	May 8, 2022	Aug 8, 2022	Nov 8, 2022	Mar 22, 2023	May 16, 2023	Aug 8, 2023	Nov 8, 2023	Mar 5, 2024	May 14, 2024	Aug 5, 2024	Nov 6, 2024	Mar 13, 2025	May 14, 2025	Aug 18, 2025	Nov 13, 2025	Mar 19, 2026	May 19, 2026	Aug 5, 2026	Nov 12, 2026
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.19	-0.23	-0.27	-0.33	-0.32	-0.33	-0.31	-0.34	-0.41	-0.43	-0.37	-0.41	-0.41	-0.45	-0.44	-0.51	-0.62	-0.56	-0.55	-0.63	-0.47	-0.23
EPS Actual	-0.13	-0.14	-0.01	-0.01	-0.17	-0.25	-0.26	-0.30	-0.31	-0.31	-0.24	-0.31	-0.26	-0.12	-0.24	-0.51	-0.46	-0.45	-0.27	-0.38	-0.41	-0.43	-0.50	-0.46	-0.60	-0.63	-0.63	-0.59	-0.43	-0.67	-
Surprise	-	-	-	-	-	-	-	-	-	-63.16%	-3.13%	-15.96%	21.21%	62.50%	27.27%	-64.52%	-35.29%	-9.76%	37.21%	-2.70%	0.00%	-4.88%	-11.11%	-4.55%	-16.60%	-1.61%	-12.50%	-7.27%	31.64%	-42.55%	-
Timing	-	-	-	-	-	After-hours	-	-	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	Pre-market	After-hours	After-hours	After-hours	-	After-hours	-

Key Statistics & Ratios

Market Cap147.67M

Enterprise Value86.74M

Trailing P/E0.00

Forward P/E0.00

Price / Sales6.82

Price / Book1.42

EPS-2.49

Book Value0.965

Revenue (TTM)21.66M

Gross Profit (TTM)13.04M

EBITDA-82.74M

Profit Margin0.00%

Operating Margin-268.25%

Return on Equity-122.68%

Return on Assets-36.87%

Shares Outstanding101.84M

Shares Float50.88M

Beta0.96

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Buy

Based on 5 analystsTarget 4.27

Strong Buy
3
Buy
1
Hold
1

Ownership Breakdown

Institutions: 29.90%
Insiders: 33.19%
Retail / Other: 36.91%

Top Fund Holders

Helium Fund Selection C-EUR
382.30K0.38%
AXAWF Eurp Ex-UK Mccp F Cap EUR
360.00K0.35%
apo Medical Opportunities R
353.65K0.35%
TEQ - Disruptive Technologies - I-II
339.06K0.33%
Aesculape SRI IC
301.00K0.30%
Paladin One F
206.90K0.20%
BNP Paribas Belgium Equity Cl EUR Acc
183.79K0.18%
Helium Fund Performance S EUR
143.50K0.14%
BlackRock Health Sciences Term Trust
112.02K0.11%
Belfius Equities Bel=Go C Cap
105.80K0.10%
GVC Gaesco T.F.T. FI
85.00K0.08%
Fidelity Nasdaq Composite Index
69.09K0.07%
TEQ - Small & Mid Cap Tech I-II
39.40K0.04%
TEQ- Disruptive Tech In I-III
36.24K0.04%
Deutsche Postbank Europafonds Plus
35.00K0.03%
BSO Euro Santé I
30.00K0.03%
Pareturn GVC Gaesco Absolute Return U
30.00K0.03%
Pareturn GVC Gaesco Euro SC Eqty Fd U
30.00K0.03%
AXA Pension Long Terme I
15.10K0.01%
Econopolis Belgian Champions A EUR Dis
15.00K0.01%